Humanized Anti-α2 Integrin Antibodies for Inhibiting Collagen Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-α2β1 integrin antibodies, particularly murine monoclonal antibodies, are limited by immune responses in humans, leading to reduced efficacy and safety concerns due to immune reactions and ineffective complement activation, necessitating the development of humanized antibodies that do not trigger adverse bleeding complications.
Innovation Solution
Development of humanized anti-α2 integrin antibodies with specific variable regions and framework regions, designed to target the α2β1 integrin without activating platelets, including forms like Fab or F(ab')2 fragments, and methods for their production and delivery, such as gene therapy using vectors to generate antibody-producing cells that home to specific tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If murine monoclonal antibodies are used to target α2β1 integrin, then the antibody can effectively bind to the target, but immune responses occur in humans leading to reduced efficacy and safety concerns
Solution Approach 1:
The patent applies parameter changes by modifying the antibody's species origin from murine to humanized. The variable regions are derived from murine antibodies while the constant regions are human, changing the immunogenicity parameter to reduce immune responses while maintaining target binding effectiveness.
Solution Approach 2:
The patent creates a composite antibody structure combining murine variable regions (for target specificity) with human constant regions (for reduced immunogenicity). This chimeric construction merges the advantages of both murine and human antibody components.
2Reliability
If anti-α2β1 integrin antibodies are used to treat inflammatory diseases, then therapeutic effect is achieved, but platelet activation and bleeding complications occur
Solution Approach 1:
The patent applies local quality by making the antibody humanized specifically in the constant regions while retaining murine variable regions. This localized modification reduces systemic immunogenicity and platelet activation while preserving the specific binding properties needed for therapeutic efficacy in inflammatory diseases.
Solution Approach 2:
The patent changes the species composition parameter of the antibody from fully murine to humanized, which alters the interaction with human platelets and reduces unwanted activation while maintaining the ability to block α2β1 integrin-mediated inflammatory responses.
Data Source
AI summary
The invention relates to anti-a2 integrin antibodies and their uses. Humunized antibodies are disclosed that bind to the I domain of a2 integrin and inhibit the interaction of a2ß1 integrin with collagen. Also disclosed are therapeutic uses of anti-a2 integrin antibodies in treating a2ß1-mediated disorders, including anti-a2 integrin antibodie s that bind to a2 integrin without activating platelets.